Document is current
Any future updates will be listed below
-
Authors
Rothgangl, Tanja https://orcid.org/0000-0001-7799-2413
Dennis, Melissa K.
Lin, Paulo J. C.
Oka, Rurika https://orcid.org/0000-0003-4107-7250
Witzigmann, Dominik https://orcid.org/0000-0002-8197-8558
Villiger, Lukas
Qi, Weihong
Hruzova, Martina
Kissling, Lucas
Lenggenhager, Daniela
Borrelli, Costanza
Egli, Sabina
Frey, Nina
Bakker, Noëlle
Walker, John A. II
Kadina, Anastasia P.
Victorov, Denis V.
Pacesa, Martin https://orcid.org/0000-0003-1560-5769
Kreutzer, Susanne
Kontarakis, Zacharias https://orcid.org/0000-0001-8825-8513
Moor, Andreas https://orcid.org/0000-0001-8715-8449
Jinek, Martin https://orcid.org/0000-0002-7601-210X
Weissman, Drew
Stoffel, Markus https://orcid.org/0000-0003-1304-5817
van Boxtel, Ruben https://orcid.org/0000-0003-1285-2836
Holden, Kevin https://orcid.org/0000-0002-3091-4124
Pardi, Norbert
Thöny, Beat
Häberle, Johannes
Tam, Ying K.
Semple, Sean C.
Schwank, Gerald https://orcid.org/0000-0003-0767-2953
- License Information
-
More Information
Article History
Received: 5 February 2021
Accepted: 23 April 2021
First Online: 19 May 2021
Competing interests
: P.J.C.L., M.D., Y.K.T. and S.C.S. are employees of Acuitas Therapeutics. K.H., J.A.W., D.V.V. and A.P.K. are employees and shareholders of Synthego Corporation. D. Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. M.J., G.S. and L.V. are named on patents and patent applications related to CRISPR–Cas technologies. The remaining authors declare no competing financial interests.
